Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery diseaseLars Wallentin, Agneta Siegbahn, Christoph Varenhorst et al.|European Heart Journal|2007Cited by 457
The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registryMichel Komajda, Francesco Cosentino, Roberto Ferrari et al.|European Heart Journal - Quality of Care and Clinical Outcomes|2019Cited by 3
Abstract 18805: Vorapaxar, A Platelet Thrombin-Receptor Antagonist, in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from the TRACER TrialMarco Valgimigli, David J. Moliterno, Robert A. Harrington et al.|Circulation|2012Cited by 2
Abstract 3217: Prasugrel 60/10 mg Compared with Clopidogrel 600/75 mg Results in Fewer Poor Responders Using Definitions of Platelet Reactivity Associated with Clinical OutcomesDavid Erlinge, Lars Wallentin, Christoph Varenhorst et al.|Circulation|2007Cited by 0